146 related articles for article (PubMed ID: 37347370)
1. Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN
Garcia-Huidobro D; Iturriaga C; Perez-Mateluna G; Fajuri P; Severino N; Urzúa M; Fraga JP; de la Cruz J; Poli C; Castro-Rodríguez JA; Fish E; Borzutzky A;
Clin Drug Investig; 2023 Jun; 43(6):447-461. PubMed ID: 37347370
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
Pandit A; Bhalani N; Bhushan BLS; Koradia P; Gargiya S; Bhomia V; Kansagra K
Int J Infect Dis; 2021 Apr; 105():516-521. PubMed ID: 33713817
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study.
Bhushan B L S; Wanve S; Koradia P; Bhomia V; Soni P; Chakraborty S; Khobragade A; Joshi S; Mendiratta SK; Kansagra KK; Parihar A; Sharma S; Patel J;
Int J Infect Dis; 2021 Oct; 111():281-287. PubMed ID: 34428542
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
[TBL] [Abstract][Full Text] [Related]
11. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial.
Tassopoulos NC; Koutelou MG; Polychronaki H; Paraloglou-Ioannides M; Hadziyannis SJ
J Viral Hepat; 1997; 4(6):387-94. PubMed ID: 9430359
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
[TBL] [Abstract][Full Text] [Related]
16. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
18. Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial.
Yuki Y; Nojima M; Hosono O; Tanaka H; Kimura Y; Satoh T; Imoto S; Uematsu S; Kurokawa S; Kashima K; Mejima M; Nakahashi-Ouchida R; Uchida Y; Marui T; Yoshikawa N; Nagamura F; Fujihashi K; Kiyono H
Lancet Microbe; 2021 Sep; 2(9):e429-e440. PubMed ID: 35544149
[TBL] [Abstract][Full Text] [Related]
19. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
Krown SE; Aeppli D; Balfour HH
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]